MeSH D010661 - phenylketonurias
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Annora Pharma | Sapropterin | Sapropterin | 2022-08-18 | |||
| BioMarin Pharmaceutical | Sapropterin | Kuvan | 2024-11-17 | 2007-12-13 | $166.199 M | Q2/23-Q1/24 |
| Pegvaliase | Palynziq | 2018-05-24 | $317.276 M | Q2/23-Q1/24 | ||
| Dipharma | Sapropterin | Sapropterin Dipharma | 2022-02-16 | |||
| Dr Reddys Laboratories | Sapropterin | Sapropterin | 2021-06-15 | |||
| Endo | Sapropterin | Sapropterin | 2019-05-10 |
Clinical Trials
Historical Success Rate
Phase 1
48%23/48
Phase 2
38%17/45
Phase 3
28%11/39
Approved: 6Overall Success rate: 5%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use